Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. - Wikidata - wikimedia - TriplyDB

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

http://www.wikidata.org/entity/Q37201405

about

Autoimmune Myopathies: Where Do We Stand?Idiopathic Inflammatory Myopathies: Clinical Approach and Management Elevated risk of venous thromboembolic events in patients with inflammatory myopathies Emerging therapeutic options for sporadic inclusion body myositis Scanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory Myopathies Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond Update in inclusion body myositis Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-Autoimmune neuromuscular disorders Immunotherapies for Immune-Mediated Myopathies: A Current Perspective Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies.Drugs in induction and treatment of idiopathic inflammatory myopathies Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.Diagnosis and treatment of the idiopathic inflammatory myopathies Inclusion body myositis associated with Sjögren's syndrome.Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA Sporadic inclusion body myositis: variability in prevalence and phenotype and influence of the MHC.Review: An update on inflammatory and autoimmune myopathies.Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.Targeted immunotherapy trials for idiopathic inflammatory myopathies.Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies.Monoclonal antibodies in neuroinflammatory diseases.Update on treatment of inclusion body myositis.Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy.Diagnosis, pathogenesis and treatment of myositis: recent advances.Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives.Abatacept as a successful therapy for myositis—a case-based review.Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken.Myositis Mimics.Idiopathic inflammatory myopathies: from immunopathogenesis to new therapeutic targets.Idiopathic Inflammatory Myopathies: an Update on Classification and Treatment with Special Focus on Juvenile Forms.Long-term observational study of sporadic inclusion body myositis.Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes.Novel approaches in the treatment of myositis and myopathies.Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis.Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle.Physical function and muscle strength in sporadic inclusion body myositis.A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities.Inclusion body myositis - pathomechanism and lessons from genetics.

P2860

Q26744554-0FCDB86C-0EF7-4437-8C55-1F83529650ED Q26744705-39EA02E3-3C7E-43C1-B3AA-50A1C5936EDF Q26746904-8DFBAA5C-0DBE-43A0-BD19-D7F27155ACAE Q26786571-4820A078-4DF9-4B20-99D3-9415F9EAE16A Q26798209-704162F1-9CF8-4033-97E8-F109FF2CF7C9 Q26800128-9815AA74-4C84-4D0B-8845-A625CFADC2E7 Q26829906-3917F769-6792-45B9-9E88-08CB7DCF1FD9 Q26863125-F2ADDE84-A88B-4A4E-8159-A00092885788 Q27021322-90A2788E-0438-47C6-B2B7-A2BC129E06A3 Q28261039-2FBA9E40-9E32-4D14-9CD0-D2D57E6E9384 Q30699742-453DEE5F-6FBB-4539-A30F-AADABFCFD898 Q33717793-BD703BB5-5706-4CC9-9D8D-B71FC2F77292 Q35281940-B1078A17-BAAD-46E7-850F-EFB5725717C0 Q35991443-0BFF4EBA-6EFF-4E2F-8507-E21D395FBC94 Q36059440-20E80BDE-082E-45D3-984C-5252CF884CEF Q37321691-C960A417-0131-4B98-839B-D757964C6AB7 Q37610500-D3C69FDD-AD85-4CF2-8D2A-EB0C642899D2 Q37686467-8AE639DC-71A7-489F-B29C-8D1485A384DA Q37820692-BEFB9743-34EF-44D6-8319-C0CE42083502 Q37968620-F2DABB20-6AD3-4A2C-B3B8-7A5E88B377B0 Q38023207-C3A0341E-BFD6-4E1A-9764-676DF63C703A Q38089081-699064CB-BE7B-4402-885B-A62628A43639 Q38092121-A1E7750B-A17C-4952-839D-F29118B5F842 Q38093096-18DA2E9A-6D29-4A59-BCB4-EAA8C48E8DFD Q38130904-381B26F5-9AEF-4F0C-9EEB-34597E3AB5C8 Q38131849-484B175F-E600-4923-AB73-E24845F4697B Q38153797-3CB809D7-501F-4A69-ABE6-4C1B9F306534 Q38184953-6A2A0DB1-4383-4D49-BDFD-8ABD5A8C4AEC Q38314711-9EE799D1-07D5-41AF-B3F3-99DF751FFC2D Q38569863-E99CA7CA-EE77-4A64-A103-60AE327300B0 Q38589301-86B315C4-65FC-4E4E-BF40-EA3AB7AD5579 Q38597575-00488650-10A8-493F-AB75-915545E14577 Q39698054-1109AA02-CDF6-4FF9-BC83-3468EAF79D87 Q40299150-6BD9B0F9-F52B-480C-B41A-5102DF98DAEA Q41977818-26B2F5F0-556A-4508-98F6-99C3DF487DF5 Q42606123-44DBBFE6-489F-4C7F-91A9-229C016D14B0 Q47195942-D9D3DE19-2CDE-4B61-ABC5-E22DBF3DBB3A Q47576235-0312123A-FC81-4471-8653-ABCDCCEECCD2 Q48906281-BD0636C1-5C5F-41CB-9B1E-2EE9ADB8D394 Q53816848-C800683B-4CB8-4015-B65C-9A5F170A136B

P2860

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

http://www.wikidata.org/entity/Q37201405

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

@en

Effect of Alemtuzumab

@nl

type

label

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

@en

Effect of Alemtuzumab

@nl

prefLabel

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

@en

Effect of Alemtuzumab

@nl

P1433

Q37201405-37AC4952-A86D-4E97-A410-727342B0C8A1

P1476

Q37201405-9241F935-E728-43ED-A7B2-30A8DEB5774C

P2093

Q37201405-12D92168-0951-462D-BDF4-2CC06D44AC9B

Q37201405-14E72F1F-B43E-4FDC-9A51-19D7D43EAD07

Q37201405-7AF94FD7-2036-42F5-B2D6-15F11F909A64

Q37201405-7F6F64AC-1032-4021-8AD4-05D4529C7F92

Q37201405-A6B56BB8-0CFA-431E-9512-F0FFBA06E8D1

Q37201405-ADCC5407-37B5-4B12-8F28-0F2AB21E7F8F

Q37201405-BF37C6C0-0D10-4225-A652-7C3228369FB9

Q37201405-CB76B7FF-67C7-44E2-94B7-E3D89035CB0A

Q37201405-E71D9E41-244D-467D-B174-C283C7628833

Q37201405-F150A993-9D73-4899-9F88-AA8389898C96

P2860

Q37201405-02C99100-ACB4-45A2-A934-6F8A13537FA8

Q37201405-0AF03DF4-3A2F-418C-8751-BB9B5B3BCAAD

Q37201405-11613BFC-3407-4811-8299-A4AF9E4B0E27

Q37201405-1208C6EB-76FE-4CEF-BC31-D8B6074C97F4

Q37201405-221F8901-0D0F-4F57-8F0A-F473822BF37F

Q37201405-250C602A-6D21-41A7-A545-73B688D74AE5

Q37201405-2EE795C4-E041-4342-B1E1-A6A32DB695EF

Q37201405-34AF6100-34EE-4516-8AA1-A3B260BE0FBF

Q37201405-4F8A9E95-3C0B-4305-B315-5312D0BC5D4D

Q37201405-51724794-C86C-4248-841D-C798750831E9

P304

Q37201405-22DCE5A5-F937-4789-9CBF-69F545DA5B3E

P31

Q37201405-33984E09-8199-426F-B179-B5E3DD0CBD2F

P356

Q37201405-1E8088D7-EC83-4F05-B6A1-B6FD5963E505

P407

Q37201405-A004BFB0-9E7A-469B-B4AB-7CD9B3FC0B4C

P433

Q37201405-492E83B2-587E-415C-8A67-34A4AB8EA4C5

P478

Q37201405-AA4C334A-6E97-4BC3-B329-BD8C896AE69A

P50

Q37201405-C87697D8-C26D-47AC-A58B-8A6C9E0BC947

P577

Q37201405-3701D269-22B9-4AEB-BBBA-1679C92179FD

P5875

Q37201405-A8890C36-64D4-422E-847E-35E6AE2E3595

P698

Q37201405-52EFBC08-5BE5-4719-83AF-2EAD02B36428

P932

Q37201405-F19EFDFE-2B81-49F9-9395-524F6B7B968D

P356

P1433

P1476

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis

@en

P2093

Allan D Kirk

http://www.w3.org/2001/XMLSchema#string

Beverly McElroy

http://www.w3.org/2001/XMLSchema#string

David A Bruno

http://www.w3.org/2001/XMLSchema#string

Ellen W Levy

http://www.w3.org/2001/XMLSchema#string

Goran Rakocevic

http://www.w3.org/2001/XMLSchema#string

James Dambrosia

http://www.w3.org/2001/XMLSchema#string

Jens Schmidt

http://www.w3.org/2001/XMLSchema#string

Joseph A Shrader

http://www.w3.org/2001/XMLSchema#string

Marinos C Dalakas

http://www.w3.org/2001/XMLSchema#string

Mohammad Salajegheh

http://www.w3.org/2001/XMLSchema#string

P2860

From Laboratory to Clinic : The Story of CAM PA TH-1

A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.

Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis.

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Campath-1H monoclonal antibody therapy.

Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study.

Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition.

Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies.

A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation.

Polymyositis, dermatomyositis and inclusion-body myositis.

P304

1536-1544

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/BRAIN/AWP104

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 6

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P50

Michael Harris-Love

P577

2009-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24439198

http://www.w3.org/2001/XMLSchema#string

P698

19454532

http://www.w3.org/2001/XMLSchema#string

P932

2685923

http://www.w3.org/2001/XMLSchema#string